Our study can suggest that combined immunohistochemical assessment for BRAF protein, PD1, and PDL1 expression in CRC could be beneficial for selecting patients for future combined immunotherapy and BRAF inhibitors. This evidence concerns the gene BRAF and colorectal carcinoma.